A New Option for Thyroid Eye Disease, No Matter How Long You've Had It
Thyroid eye disease (TED) is an autoimmune condition, often occurring alongside Graves' disease, in which the immune system attacks the tissue around the eyes, causing bulging, pain, double vision, and in severe cases, vision loss. Until recently, patients had only one FDA-approved targeted treatment option, and it was studied and used primarily in the active, actively inflamed phase of the disease. That left a real gap for the many patients who've been living with chronic TED symptoms for years, well past that initial active window, with fewer proven options available to them.
On June 26, 2026, the FDA approved Lumvoa (veligrotug-vvze), made by Viridian Therapeutics, for the treatment of thyroid eye disease regardless of whether a patient is in the active, inflammatory phase or the later chronic phase. Lumvoa is a monoclonal antibody that targets the insulin-like growth factor-1 receptor (IGF-1R), a protein that plays a central role in driving the inflammation and tissue changes behind TED. It's given as five intravenous infusions over 12 weeks, spaced three weeks apart.
The approval was based on two Phase 3 placebo-controlled trials that tested Lumvoa in both active and chronic TED populations, and both showed statistically significant and clinically meaningful improvement in disease signs and symptoms by week 15. The FDA granted the drug Priority Review and Breakthrough Therapy Designation, both of which reflect the agency's view that this addressed a significant unmet medical need, and Lumvoa now becomes the second FDA-approved targeted therapy for TED, introducing real competition and choice where patients previously had essentially one option.
What sets this approval apart isn't just that it's a new drug, it's specifically that chronic-phase patients, those who've been managing TED symptoms for years without a targeted option built for their stage of disease, now have real clinical trial evidence behind a treatment designed to work for them too. That distinction matters because TED symptoms, even in the chronic phase, can still meaningfully affect vision, appearance, and quality of life, and patients in that phase have historically had fewer good answers.
If you have thyroid eye disease, whether newly active or longstanding, this is a meaningful development worth discussing with your ophthalmologist or endocrinologist, particularly if you were told in the past that treatment options were limited because too much time had passed since your disease became active. Having two approved options on the market may also open the door to more conversations about which drug's infusion schedule and side effect profile fits your life better.